Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
LPI (LP Information)' newest research report, the “Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industry Forecast” looks at past sales and reviews total world Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales in 2022, providing a comprehensive analysis by region and market sector of projected Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales for 2023 through 2029. With Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) industry.
This Insight Report provides a comprehensive analysis of the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa).
The global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size is projected to grow from US$ 1109.1 million in 2022 to US$ 1384.2 million in 2029; it is expected to grow at a CAGR of 1384.2 from 2023 to 2029.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
This report presents a comprehensive overview, market shares, and growth opportunities of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market?
What factors are driving Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market opportunities vary by end market size?
How does Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
LPI (LP Information)' newest research report, the “Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industry Forecast” looks at past sales and reviews total world Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales in 2022, providing a comprehensive analysis by region and market sector of projected Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales for 2023 through 2029. With Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) industry.
This Insight Report provides a comprehensive analysis of the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa).
The global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size is projected to grow from US$ 1109.1 million in 2022 to US$ 1384.2 million in 2029; it is expected to grow at a CAGR of 1384.2 from 2023 to 2029.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
This report presents a comprehensive overview, market shares, and growth opportunities of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- 60 KIU
- 50 KIU
- Bleeding
- Surgery Assisted
- Glanzmann Plateletasthenia
- Hemophilia B
- Hemophilia A
- Head Trauma
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- BMS
- Generium
- Novo Nordisk
- Shire (Baxter)
- Bayer
- CSL
- Pfizer
- Grifols
- Biogen
- Octapharma
- NovoNordisk
- Greencross
- Kedrion
- BPL
- Hualan Bio
- RAAS
- Suzhou Alphamab
What is the 10-year outlook for the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market?
What factors are driving Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market opportunities vary by end market size?
How does Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country/Region, 2018, 2022 & 2029
2.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Type
2.2.1 60 KIU
2.2.2 50 KIU
2.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
2.3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
2.3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue and Market Share by Type (2018-2023)
2.3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Type (2018-2023)
2.4 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Application
2.4.1 Bleeding
2.4.2 Surgery Assisted
2.4.3 Glanzmann Plateletasthenia
2.4.4 Hemophilia B
2.4.5 Hemophilia A
2.4.6 Head Trauma
2.4.7 Others
2.5 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
2.5.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Market Share by Application (2018-2023)
2.5.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue and Market Share by Application (2018-2023)
2.5.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Application (2018-2023)
3 GLOBAL EPTACOG ALFA (RECOMBINANT HUMAN COAGULATION FACTOR VIIA) BY COMPANY
3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Breakdown Data by Company
3.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Company (2018-2023)
3.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company (2018-2023)
3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Company (2018-2023)
3.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2018-2023)
3.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company (2018-2023)
3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Company
3.4 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Location Distribution
3.4.2 Players Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR EPTACOG ALFA (RECOMBINANT HUMAN COAGULATION FACTOR VIIA) BY GEOGRAPHIC REGION
4.1 World Historic Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Geographic Region (2018-2023)
4.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country/Region (2018-2023)
4.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Country/Region (2018-2023)
4.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Country/Region (2018-2023)
4.3 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.4 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.5 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.6 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
5 AMERICAS
5.1 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country
5.1.1 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023)
5.1.2 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023)
5.2 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
5.3 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region
6.1.1 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2018-2023)
6.1.2 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2018-2023)
6.2 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
6.3 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country
7.1.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023)
7.1.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023)
7.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
7.3 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country
8.1.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023)
8.1.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023)
8.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
8.3 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
10.3 Manufacturing Process Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
10.4 Industry Chain Structure of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors
11.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customer
12 WORLD FORECAST REVIEW FOR EPTACOG ALFA (RECOMBINANT HUMAN COAGULATION FACTOR VIIA) BY GEOGRAPHIC REGION
12.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size Forecast by Region
12.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Region (2024-2029)
12.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Type
12.7 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 BMS
13.1.1 BMS Company Information
13.1.2 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.1.3 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 BMS Main Business Overview
13.1.5 BMS Latest Developments
13.2 Generium
13.2.1 Generium Company Information
13.2.2 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.2.3 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Generium Main Business Overview
13.2.5 Generium Latest Developments
13.3 Novo Nordisk
13.3.1 Novo Nordisk Company Information
13.3.2 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.3.3 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novo Nordisk Main Business Overview
13.3.5 Novo Nordisk Latest Developments
13.4 Shire (Baxter)
13.4.1 Shire (Baxter) Company Information
13.4.2 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.4.3 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Shire (Baxter) Main Business Overview
13.4.5 Shire (Baxter) Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.5.3 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 CSL
13.6.1 CSL Company Information
13.6.2 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.6.3 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CSL Main Business Overview
13.6.5 CSL Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.7.3 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Grifols
13.8.1 Grifols Company Information
13.8.2 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.8.3 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Grifols Main Business Overview
13.8.5 Grifols Latest Developments
13.9 Biogen
13.9.1 Biogen Company Information
13.9.2 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.9.3 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Biogen Main Business Overview
13.9.5 Biogen Latest Developments
13.10 Octapharma
13.10.1 Octapharma Company Information
13.10.2 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.10.3 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Octapharma Main Business Overview
13.10.5 Octapharma Latest Developments
13.11 NovoNordisk
13.11.1 NovoNordisk Company Information
13.11.2 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.11.3 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 NovoNordisk Main Business Overview
13.11.5 NovoNordisk Latest Developments
13.12 Greencross
13.12.1 Greencross Company Information
13.12.2 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.12.3 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Greencross Main Business Overview
13.12.5 Greencross Latest Developments
13.13 Kedrion
13.13.1 Kedrion Company Information
13.13.2 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.13.3 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Kedrion Main Business Overview
13.13.5 Kedrion Latest Developments
13.14 BPL
13.14.1 BPL Company Information
13.14.2 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.14.3 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 BPL Main Business Overview
13.14.5 BPL Latest Developments
13.15 Hualan Bio
13.15.1 Hualan Bio Company Information
13.15.2 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.15.3 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Hualan Bio Main Business Overview
13.15.5 Hualan Bio Latest Developments
13.16 RAAS
13.16.1 RAAS Company Information
13.16.2 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.16.3 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 RAAS Main Business Overview
13.16.5 RAAS Latest Developments
13.17 Suzhou Alphamab
13.17.1 Suzhou Alphamab Company Information
13.17.2 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.17.3 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Suzhou Alphamab Main Business Overview
13.17.5 Suzhou Alphamab Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country/Region, 2018, 2022 & 2029
2.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Type
2.2.1 60 KIU
2.2.2 50 KIU
2.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
2.3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
2.3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue and Market Share by Type (2018-2023)
2.3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Type (2018-2023)
2.4 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Application
2.4.1 Bleeding
2.4.2 Surgery Assisted
2.4.3 Glanzmann Plateletasthenia
2.4.4 Hemophilia B
2.4.5 Hemophilia A
2.4.6 Head Trauma
2.4.7 Others
2.5 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
2.5.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Market Share by Application (2018-2023)
2.5.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue and Market Share by Application (2018-2023)
2.5.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Application (2018-2023)
3 GLOBAL EPTACOG ALFA (RECOMBINANT HUMAN COAGULATION FACTOR VIIA) BY COMPANY
3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Breakdown Data by Company
3.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Company (2018-2023)
3.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company (2018-2023)
3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Company (2018-2023)
3.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2018-2023)
3.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company (2018-2023)
3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Company
3.4 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Location Distribution
3.4.2 Players Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR EPTACOG ALFA (RECOMBINANT HUMAN COAGULATION FACTOR VIIA) BY GEOGRAPHIC REGION
4.1 World Historic Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Geographic Region (2018-2023)
4.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country/Region (2018-2023)
4.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales by Country/Region (2018-2023)
4.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue by Country/Region (2018-2023)
4.3 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.4 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.5 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
4.6 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth
5 AMERICAS
5.1 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country
5.1.1 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023)
5.1.2 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023)
5.2 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
5.3 Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region
6.1.1 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2018-2023)
6.1.2 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2018-2023)
6.2 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
6.3 APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country
7.1.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023)
7.1.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023)
7.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
7.3 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Country
8.1.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023)
8.1.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023)
8.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type
8.3 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
10.3 Manufacturing Process Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
10.4 Industry Chain Structure of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors
11.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customer
12 WORLD FORECAST REVIEW FOR EPTACOG ALFA (RECOMBINANT HUMAN COAGULATION FACTOR VIIA) BY GEOGRAPHIC REGION
12.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size Forecast by Region
12.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Region (2024-2029)
12.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Type
12.7 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 BMS
13.1.1 BMS Company Information
13.1.2 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.1.3 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 BMS Main Business Overview
13.1.5 BMS Latest Developments
13.2 Generium
13.2.1 Generium Company Information
13.2.2 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.2.3 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Generium Main Business Overview
13.2.5 Generium Latest Developments
13.3 Novo Nordisk
13.3.1 Novo Nordisk Company Information
13.3.2 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.3.3 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novo Nordisk Main Business Overview
13.3.5 Novo Nordisk Latest Developments
13.4 Shire (Baxter)
13.4.1 Shire (Baxter) Company Information
13.4.2 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.4.3 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Shire (Baxter) Main Business Overview
13.4.5 Shire (Baxter) Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.5.3 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 CSL
13.6.1 CSL Company Information
13.6.2 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.6.3 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CSL Main Business Overview
13.6.5 CSL Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.7.3 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Grifols
13.8.1 Grifols Company Information
13.8.2 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.8.3 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Grifols Main Business Overview
13.8.5 Grifols Latest Developments
13.9 Biogen
13.9.1 Biogen Company Information
13.9.2 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.9.3 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Biogen Main Business Overview
13.9.5 Biogen Latest Developments
13.10 Octapharma
13.10.1 Octapharma Company Information
13.10.2 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.10.3 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Octapharma Main Business Overview
13.10.5 Octapharma Latest Developments
13.11 NovoNordisk
13.11.1 NovoNordisk Company Information
13.11.2 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.11.3 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 NovoNordisk Main Business Overview
13.11.5 NovoNordisk Latest Developments
13.12 Greencross
13.12.1 Greencross Company Information
13.12.2 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.12.3 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Greencross Main Business Overview
13.12.5 Greencross Latest Developments
13.13 Kedrion
13.13.1 Kedrion Company Information
13.13.2 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.13.3 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Kedrion Main Business Overview
13.13.5 Kedrion Latest Developments
13.14 BPL
13.14.1 BPL Company Information
13.14.2 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.14.3 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 BPL Main Business Overview
13.14.5 BPL Latest Developments
13.15 Hualan Bio
13.15.1 Hualan Bio Company Information
13.15.2 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.15.3 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Hualan Bio Main Business Overview
13.15.5 Hualan Bio Latest Developments
13.16 RAAS
13.16.1 RAAS Company Information
13.16.2 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.16.3 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 RAAS Main Business Overview
13.16.5 RAAS Latest Developments
13.17 Suzhou Alphamab
13.17.1 Suzhou Alphamab Company Information
13.17.2 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
13.17.3 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 Suzhou Alphamab Main Business Overview
13.17.5 Suzhou Alphamab Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 60 KIU
Table 4. Major Players of 50 KIU
Table 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Table 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type (2018-2023) & ($ million)
Table 8. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2018-2023)
Table 9. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 11. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Table 12. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application (2018-2023)
Table 13. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application (2018-2023)
Table 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Company (2018-2023) & (K Units)
Table 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company (2018-2023)
Table 17. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company (2018-2023)
Table 19. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Producing Area Distribution and Sales Area
Table 21. Players Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Products Offered
Table 22. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Geographic Region (2018-2023)
Table 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country/Region (2018-2023)
Table 31. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023) & (K Units)
Table 34. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2018-2023)
Table 35. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2018-2023)
Table 37. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 38. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 39. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2018-2023) & (K Units)
Table 40. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region (2018-2023)
Table 41. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Region (2018-2023)
Table 43. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 44. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 45. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023) & (K Units)
Table 46. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2018-2023)
Table 47. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2018-2023)
Table 49. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 50. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 58. Key Market Challenges & Risks of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 59. Key Industry Trends of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 60. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors List
Table 63. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customer List
Table 64. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. BMS Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 79. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 80. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. BMS Main Business
Table 82. BMS Latest Developments
Table 83. Generium Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 84. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 85. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Generium Main Business
Table 87. Generium Latest Developments
Table 88. Novo Nordisk Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 89. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 90. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Novo Nordisk Main Business
Table 92. Novo Nordisk Latest Developments
Table 93. Shire (Baxter) Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 94. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 95. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Shire (Baxter) Main Business
Table 97. Shire (Baxter) Latest Developments
Table 98. Bayer Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 99. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 100. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Bayer Main Business
Table 102. Bayer Latest Developments
Table 103. CSL Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 104. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 105. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. CSL Main Business
Table 107. CSL Latest Developments
Table 108. Pfizer Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 110. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Grifols Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 114. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 115. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Grifols Main Business
Table 117. Grifols Latest Developments
Table 118. Biogen Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 119. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 120. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Biogen Main Business
Table 122. Biogen Latest Developments
Table 123. Octapharma Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 124. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 125. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Octapharma Main Business
Table 127. Octapharma Latest Developments
Table 128. NovoNordisk Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 129. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 130. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. NovoNordisk Main Business
Table 132. NovoNordisk Latest Developments
Table 133. Greencross Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 134. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 135. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Greencross Main Business
Table 137. Greencross Latest Developments
Table 138. Kedrion Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 139. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 140. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 141. Kedrion Main Business
Table 142. Kedrion Latest Developments
Table 143. BPL Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 144. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 145. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 146. BPL Main Business
Table 147. BPL Latest Developments
Table 148. Hualan Bio Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 149. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 150. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 151. Hualan Bio Main Business
Table 152. Hualan Bio Latest Developments
Table 153. RAAS Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 154. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 155. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 156. RAAS Main Business
Table 157. RAAS Latest Developments
Table 158. Suzhou Alphamab Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 159. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 160. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 161. Suzhou Alphamab Main Business
Table 162. Suzhou Alphamab Latest Developments
Table 1. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 60 KIU
Table 4. Major Players of 50 KIU
Table 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Table 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type (2018-2023) & ($ million)
Table 8. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2018-2023)
Table 9. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Type (2018-2023) & (US$/Unit)
Table 10. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 11. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Table 12. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application (2018-2023)
Table 13. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application (2018-2023)
Table 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Application (2018-2023) & (US$/Unit)
Table 15. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Company (2018-2023) & (K Units)
Table 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company (2018-2023)
Table 17. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company (2018-2023)
Table 19. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sale Price by Company (2018-2023) & (US$/Unit)
Table 20. Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Producing Area Distribution and Sales Area
Table 21. Players Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Products Offered
Table 22. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Geographic Region (2018-2023) & (K Units)
Table 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Geographic Region (2018-2023)
Table 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country/Region (2018-2023) & (K Units)
Table 30. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country/Region (2018-2023)
Table 31. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023) & (K Units)
Table 34. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2018-2023)
Table 35. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2018-2023)
Table 37. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 38. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 39. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2018-2023) & (K Units)
Table 40. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region (2018-2023)
Table 41. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Region (2018-2023)
Table 43. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 44. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 45. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023) & (K Units)
Table 46. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2018-2023)
Table 47. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2018-2023)
Table 49. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 50. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 51. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2018-2023) & (K Units)
Table 52. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2018-2023) & (K Units)
Table 56. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2018-2023) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 58. Key Market Challenges & Risks of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 59. Key Industry Trends of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Table 60. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors List
Table 63. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customer List
Table 64. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Region (2024-2029) & (K Units)
Table 65. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2024-2029) & (K Units)
Table 67. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Region (2024-2029) & (K Units)
Table 69. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Country (2024-2029) & (K Units)
Table 73. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Type (2024-2029) & (K Units)
Table 75. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Forecast by Application (2024-2029) & (K Units)
Table 77. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. BMS Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 79. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 80. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 81. BMS Main Business
Table 82. BMS Latest Developments
Table 83. Generium Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 84. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 85. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 86. Generium Main Business
Table 87. Generium Latest Developments
Table 88. Novo Nordisk Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 89. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 90. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 91. Novo Nordisk Main Business
Table 92. Novo Nordisk Latest Developments
Table 93. Shire (Baxter) Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 94. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 95. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 96. Shire (Baxter) Main Business
Table 97. Shire (Baxter) Latest Developments
Table 98. Bayer Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 99. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 100. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 101. Bayer Main Business
Table 102. Bayer Latest Developments
Table 103. CSL Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 104. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 105. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 106. CSL Main Business
Table 107. CSL Latest Developments
Table 108. Pfizer Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 109. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 110. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 111. Pfizer Main Business
Table 112. Pfizer Latest Developments
Table 113. Grifols Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 114. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 115. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 116. Grifols Main Business
Table 117. Grifols Latest Developments
Table 118. Biogen Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 119. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 120. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 121. Biogen Main Business
Table 122. Biogen Latest Developments
Table 123. Octapharma Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 124. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 125. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 126. Octapharma Main Business
Table 127. Octapharma Latest Developments
Table 128. NovoNordisk Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 129. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 130. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 131. NovoNordisk Main Business
Table 132. NovoNordisk Latest Developments
Table 133. Greencross Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 134. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 135. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 136. Greencross Main Business
Table 137. Greencross Latest Developments
Table 138. Kedrion Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 139. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 140. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 141. Kedrion Main Business
Table 142. Kedrion Latest Developments
Table 143. BPL Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 144. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 145. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 146. BPL Main Business
Table 147. BPL Latest Developments
Table 148. Hualan Bio Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 149. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 150. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 151. Hualan Bio Main Business
Table 152. Hualan Bio Latest Developments
Table 153. RAAS Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 154. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 155. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 156. RAAS Main Business
Table 157. RAAS Latest Developments
Table 158. Suzhou Alphamab Basic Information, Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturing Base, Sales Area and Its Competitors
Table 159. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolios and Specifications
Table 160. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 161. Suzhou Alphamab Main Business
Table 162. Suzhou Alphamab Latest Developments
LIST OF FIGURES
Figure 1. Picture of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 60 KIU
Figure 10. Product Picture of 50 KIU
Figure 11. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type in 2022
Figure 12. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2018-2023)
Figure 13. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Bleeding
Figure 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Bleeding (2018-2023) & (K Units)
Figure 15. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Surgery Assisted
Figure 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Surgery Assisted (2018-2023) & (K Units)
Figure 17. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Glanzmann Plateletasthenia
Figure 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Glanzmann Plateletasthenia (2018-2023) & (K Units)
Figure 19. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Hemophilia B
Figure 20. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Hemophilia B (2018-2023) & (K Units)
Figure 21. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Hemophilia A
Figure 22. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Hemophilia A (2018-2023) & (K Units)
Figure 23. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Head Trauma
Figure 24. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Head Trauma (2018-2023) & (K Units)
Figure 25. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Others
Figure 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Others (2018-2023) & (K Units)
Figure 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2022)
Figure 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application in 2022
Figure 29. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market by Company in 2022 (K Units)
Figure 30. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company in 2022
Figure 31. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market by Company in 2022 ($ Million)
Figure 32. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company in 2022
Figure 33. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Geographic Region (2018-2023)
Figure 34. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Geographic Region in 2022
Figure 35. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 36. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 37. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 38. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 39. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 40. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 41. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 42. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 43. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2022
Figure 44. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2022
Figure 45. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 46. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 47. United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 48. Canada Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 49. Mexico Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 50. Brazil Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 51. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region in 2022
Figure 52. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Regions in 2022
Figure 53. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 54. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 55. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 56. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 57. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 58. Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 59. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 60. Australia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 61. China Taiwan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 62. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2022
Figure 63. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2022
Figure 64. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 65. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 66. Germany Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 67. France Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 68. UK Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 69. Italy Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 70. Russia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 71. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2022
Figure 72. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2022
Figure 73. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 74. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 75. Egypt Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 76. South Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 77. Israel Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 78. Turkey Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 79. GCC Country Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in 2022
Figure 81. Manufacturing Process Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 82. Industry Chain Structure of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 83. Channels of Distribution
Figure 84. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Forecast by Region (2024-2029)
Figure 85. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Region (2024-2029)
Figure 86. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Forecast by Type (2024-2029)
Figure 87. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Type (2024-2029)
Figure 88. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Forecast by Application (2024-2029)
Figure 89. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 60 KIU
Figure 10. Product Picture of 50 KIU
Figure 11. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type in 2022
Figure 12. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2018-2023)
Figure 13. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Bleeding
Figure 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Bleeding (2018-2023) & (K Units)
Figure 15. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Surgery Assisted
Figure 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Surgery Assisted (2018-2023) & (K Units)
Figure 17. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Glanzmann Plateletasthenia
Figure 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Glanzmann Plateletasthenia (2018-2023) & (K Units)
Figure 19. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Hemophilia B
Figure 20. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Hemophilia B (2018-2023) & (K Units)
Figure 21. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Hemophilia A
Figure 22. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Hemophilia A (2018-2023) & (K Units)
Figure 23. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Head Trauma
Figure 24. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Head Trauma (2018-2023) & (K Units)
Figure 25. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Consumed in Others
Figure 26. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market: Others (2018-2023) & (K Units)
Figure 27. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2022)
Figure 28. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application in 2022
Figure 29. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market by Company in 2022 (K Units)
Figure 30. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Company in 2022
Figure 31. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market by Company in 2022 ($ Million)
Figure 32. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Company in 2022
Figure 33. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Geographic Region (2018-2023)
Figure 34. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Geographic Region in 2022
Figure 35. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 36. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 37. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 38. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 39. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 40. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 41. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2018-2023 (K Units)
Figure 42. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2018-2023 ($ Millions)
Figure 43. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2022
Figure 44. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2022
Figure 45. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 46. Americas Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 47. United States Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 48. Canada Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 49. Mexico Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 50. Brazil Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 51. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region in 2022
Figure 52. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Regions in 2022
Figure 53. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 54. APAC Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 55. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 56. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 57. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 58. Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 59. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 60. Australia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 61. China Taiwan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 62. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2022
Figure 63. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2022
Figure 64. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 65. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 66. Germany Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 67. France Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 68. UK Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 69. Italy Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 70. Russia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 71. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country in 2022
Figure 72. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country in 2022
Figure 73. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2018-2023)
Figure 74. Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2018-2023)
Figure 75. Egypt Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 76. South Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 77. Israel Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 78. Turkey Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 79. GCC Country Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth 2018-2023 ($ Millions)
Figure 80. Manufacturing Cost Structure Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in 2022
Figure 81. Manufacturing Process Analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 82. Industry Chain Structure of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
Figure 83. Channels of Distribution
Figure 84. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Forecast by Region (2024-2029)
Figure 85. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Region (2024-2029)
Figure 86. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Forecast by Type (2024-2029)
Figure 87. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Type (2024-2029)
Figure 88. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share Forecast by Application (2024-2029)
Figure 89. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share Forecast by Application (2024-2029)
